Deep brain stimulation - Neuromodulation.co

Obsessive-compulsive disorder

Obsessive-compulsive disorder (OCD) Obsessive–compulsive disorder (OCD) is one of the most debilitating psychiatric conditions, marked by persistent intrusive thoughts and repetitive behaviors that can dominate a person’s life. While many individuals respond to cognitive behavioral therapy (CBT) or medications such as SSRIs, a significant percentage—often referred to as “treatment-resistant OCD”—continue to experience severe, life-limiting symptoms despite years of care. For this group, neuromodulation has emerged as a powerful and promising option. Among these neuromodulation strategies, Deep Brain Stimulation (DBS) stands out as one of the most advanced and continuously evolving interventions. For individuals grappling with obsessive-compulsive disorder, daily life can become a challenging struggle against intrusive thoughts and compulsive behaviors that can be debilitating. Obsessive-compulsive disorder is often misunderstood. Many believe it’s just a quirk or a preference for cleanliness. However, obsessive-compulsive disorder is a serious mental health condition that demands understanding and compassion. DBS is already well-established in the treatment of movement disorders such as Parkinson’s disease, dystonia, and essential tremor. Its growing use in psychiatric conditions reflects a major shift in how we understand the brain: not as a static organ but as a dynamic network that can be modulated, retrained, and guided back into healthier functioning. In the context of OCD, DBS does not “erase” intrusive thoughts or forcefully suppress compulsions. Instead, it gently modulates the dysfunctional brain circuits that keep the cycle of obsession and compulsion locked in place. Through continuous, adjustable stimulation, DBS helps restore flexibility in neural networks, enabling patients to respond more effectively to therapy, develop healthier coping strategies, and regain control over their daily lives. OCD as a Circuit Disorder Understanding obsessive-compulsive disorder as a condition deeply rooted in neurobiology allows for better treatment approaches and empathetic support for those affected. In recent decades, neuroscience has shifted toward understanding OCD not as a purely chemical imbalance but as a network-based disorder—a condition rooted in dysfunction across interconnected regions of the brain. Key pathways known as the cortico-striato-thalamo-cortical (CSTC) circuits are consistently implicated. These pathways regulate risk assessment, reward systems, habit formation, and emotional regulation. When these circuits become overactive or “stuck,” intrusive thoughts gain excessive weight, and compulsive rituals become rigid, automatic responses. Obsessive-compulsive disorder affects various aspects of a person’s life, not just their behavior, emphasizing the need for comprehensive treatment strategies. The rationale for DBS arises from this scientific model. Rather than flooding the entire brain with medication or relying only on behavioral strategies, DBS directly targets the circuits responsible for the symptoms. This precision makes it particularly effective for patients who have exhausted conventional therapies. Recognizing obsessive-compulsive disorder as a network-based disorder reshapes how we approach treatment and support for those who suffer from it. Why DBS for OCD? People with obsessive-compulsive disorder frequently find their compulsions interfere with daily life, making it crucial to explore innovative treatments like DBS. DBS is typically considered for individuals who have: Severe, chronic OCD, lasting many years Minimal or no response to multiple medication trials Inadequate improvement from extensive cognitive behavioral therapy, especially exposure and response prevention (ERP) Functional impairment so significant that daily activities—work, relationships, self-care—are severely affected For many families, the journey through OCD treatments can feel long, exhausting, and discouraging. Patients may cycle through medications for years, often experiencing side effects without meaningful relief. Therapy can be effective but may become nearly impossible when obsessions are overwhelming or compulsions consume hours each day. DBS offers hope for these individuals because it intervenes at a neurological level that medications alone cannot reach. How DBS Works in OCD DBS uses implanted electrodes to deliver electrical pulses to targeted areas of the brain. These electrodes are connected to a neurostimulator—similar to a cardiac pacemaker—that sends continuous impulses to regulate abnormal brain activity. For OCD, common targets include: The ventral capsule/ventral striatum (VC/VS) The anterior limb of the internal capsule (ALIC) The nucleus accumbens (NAcc) Subthalamic nucleus (STN) (less common but promising in some studies) These regions are critical nodes in the brain’s reward and habit-forming circuits. When OCD is severe, they tend to become overly rigid, generating repetitive emotional and cognitive loops. DBS works by modulating these loops, decreasing hyperconnectivity, and restoring balance across the network. The Human Impact of DBS For a person living with treatment-resistant OCD, each day can feel like a battle. Simple tasks—washing hands, checking if appliances are off, arranging items symmetrically, or avoiding intrusive thoughts—can consume hours. Many individuals isolate themselves, withdraw socially, or become dependent on caregivers. Some cannot work, attend school, or maintain relationships. The emotional toll is often immense. Living with obsessive-compulsive disorder means navigating a landscape of anxiety and fear, making effective treatment options essential for recovery. DBS has the potential to change that trajectory. Its effects are not instantaneous, but as neural circuits gradually respond to stimulation, many patients begin to regain moments of clarity, flexibility, and control. Tasks that once felt impossible become tolerable. Therapy becomes more effective. Life begins to open up again. The stories of DBS patients echo a common theme: not perfection, but progress; not an absence of thoughts, but the return of choice. People describe becoming “unstuck” for the first time in years. Scientific Evidence & Growing Acceptance DBS for OCD is one of the few psychiatric applications of neuromodulation that has received regulatory approvals in certain regions. The U.S. FDA granted a Humanitarian Device Exemption (HDE) for DBS in severe OCD, recognizing its potential for patients with few remaining treatment options. Multiple long-term studies show durable improvements, often with reductions of 40–60% in symptom severity as measured by the Yale-Brown Obsessive Compulsive Scale (Y-BOCS). Some individuals achieve partial remission, while others attain substantial functional gains even if some symptoms remain. Obsessive-compulsive disorder can lead to significant emotional distress, highlighting the importance of timely and effective interventions for those affected. Importantly, DBS is adjustable and reversible—unlike lesion procedures used in psychosurgery decades ago. Modern DBS allows clinicians to: Change stimulation parameters Adjust targets Turn stimulation on or off Fine-tune therapy over months or years This level

Drug-Resistant Epilepsy with Dystonia

Drug-Resistant Epilepsy & Dystonia Drug Resistant Epilepsy is a chronic neurological disorder characterized by recurrent, unprovoked seizures arising from abnormal electrical activity in the brain. Although antiseizure medications are the primary treatment, approximately 30% of patients continue to experience disabling seizures despite adequate trials of at least two appropriate medications. This subgroup is defined as drug-resistant epilepsy (DRE) and often faces substantial impairments in quality of life, including cognitive difficulties, psychological distress, social limitations, and increased risk of injury (Zangiabadi et al., 2019; Vetkas et al., 2022). In children, DRE is particularly impactful, interrupting development, education, and psychosocial functioning, and frequently requiring advanced neuromodulation or surgical interventions (Starnes et al., 2019; Uchitel et al., 2025). Dystonia is a movement disorder characterized by involuntary, sustained, or intermittent muscle contractions resulting in abnormal postures or repetitive movements. It may be primary/genetic (e.g., DYT1) or secondary due to brain injury, metabolic disorders, or neurodegenerative conditions. Many patients show limited or incomplete response to oral medications and botulinum toxin, particularly when dystonia is generalized or segmental (Rodrigues et al., 2019). Severe dystonia can significantly restrict mobility, daily activities, and social participation, and may be associated with pain, exhaustion, and musculoskeletal complications (Fan et al., 2021; Hock et al., 2022). Both DRE and dystonia share a common challenge: they can remain refractory to conventional medical therapy and often require advanced treatments targeting disrupted neural circuits. Deep brain stimulation (DBS) has emerged as a key therapeutic option for these conditions, offering the possibility of meaningful improvement when standard treatments fail. As understanding of brain networks grows, DBS continues to expand as a safe, programmable, and effective therapy across both epilepsy and movement disorders. Understanding Drug-Resistant Epilepsy Why DBS for DRE and Dystonia? Deep brain stimulation (DBS) has become an essential therapeutic option for patients with neurological conditions that do not respond adequately to standard treatments. In drug-resistant epilepsy (DRE), ongoing seizures persist despite trials of at least two appropriate antiseizure medications. For many of these patients, resective surgery may not be possible due to multifocal seizure onset, involvement of eloquent cortex, or generalized seizure networks. DBS offers a reversible, programmable, and network-level intervention, making it suitable for patients who are not candidates for curative surgery. Clinical evidence consistently demonstrates that DBS—particularly targeting the anterior nucleus of the thalamus (ANT) and centromedian nucleus (CMN)—reduces seizure frequency and improves long-term responder rates in patients with refractory focal and generalized epilepsies (Vetkas et al., 2022; Zangiabadi et al., 2019; Dhaliwal et al., 2025). Pediatric data also show significant benefit, with many children achieving meaningful seizure reduction when other therapies fail (Starnes et al., 2019; Uchitel et al., 2025). In dystonia, medication response is often limited, especially in generalized or segmental forms. Oral agents frequently provide only partial relief, while botulinum toxin injections may be insufficient for widespread muscle groups. DBS—most commonly targeting the globus pallidus internus (GPi)—has demonstrated robust improvements in motor severity, daily functioning, and quality of life, particularly in primary dystonias such as DYT1 (Rodrigues et al., 2019; Fan et al., 2021). Long-term randomized and observational studies report sustained benefit for up to 10–15 years, with high patient satisfaction and durable symptom control (Hock et al., 2022). Across both conditions, the advantages of DBS include adjustability, reversibility, the ability to tailor stimulation to patient needs, and the potential to modulate dysfunctional circuits without removing or destroying brain tissue. For individuals living with persistent seizures or disabling dystonia despite optimal medical therapy, DBS offers one of the most effective and flexible advanced neuromodulation treatments available today. DBS Procedure & Targets Deep brain stimulation (DBS) for drug-resistant epilepsy and dystonia involves implanting thin electrodes into specific deep brain structures that regulate abnormal electrical or motor network activity. The procedure is performed using stereotactic neurosurgical techniques, guided by high-resolution MRI and CT imaging. In many centers, microelectrode recordings or test stimulation are used intraoperatively to refine placement and confirm functional accuracy (Zangiabadi et al., 2019). Once positioned, the electrodes are connected to an implantable pulse generator (IPG) placed under the skin of the chest. Programming begins a few weeks later and is adjusted over multiple sessions to optimize symptom control while minimizing side effects (Starnes et al., 2019). Targets in Drug-Resistant Epilepsy Several brain regions have been explored for epilepsy DBS, but the most established target is the anterior nucleus of the thalamus (ANT). ANT plays a key role in seizure propagation through the Papez circuit, and stimulation here consistently reduces seizure frequency in focal and multifocal epilepsies (Vetkas et al., 2022; Dhaliwal et al., 2025). The centromedian nucleus (CMN) is another important target, particularly effective for generalized epilepsies and syndromes such as Lennox–Gastaut, given its role in widespread thalamocortical activation (Zangiabadi et al., 2019; Yassin et al., 2024). In select patients, especially those with mesial temporal lobe epilepsy, hippocampal DBS has shown benefit by directly modulating seizure-generating networks, although this remains less widely adopted (Touma et al., 2022). Pediatric experiences mirror adult findings, with ANT and CMN DBS demonstrating meaningful seizure reduction when other surgical options are not possible (Uchitel et al., 2025; Starnes et al., 2019). Targets in Dystonia In dystonia, the primary and most effective DBS target is the globus pallidus internus (GPi). GPi stimulation improves abnormal muscle contractions, reduces involuntary movements, and provides substantial functional gains, particularly in primary dystonia (Rodrigues et al., 2019; Fan et al., 2021). The subthalamic nucleus (STN) is an alternative target with faster onset of benefit and strong long-term results in select cases. Head-to-head long-term comparisons show durable improvements for both GPi and STN, with some differences based on dystonia subtype and symptom profile (Hock et al., 2022). Clinical Outcomes & Long-Term Efficacy Deep brain stimulation (DBS) has demonstrated significant and durable clinical benefits for both drug-resistant epilepsy (DRE) and dystonia, with a growing body of evidence from randomized trials, long-term cohort studies, and pediatric series. Clinical Outcomes in Drug-Resistant Epilepsy: Across multiple systematic reviews and meta-analyses, ANT-DBS consistently shows meaningful seizure reduction in adults with focal and multifocal DRE.

Parkinsons Disease – Deep Brain Stimulation

Parkinson’s Disease Overview Parkinsons disease (PD), is a chronic, progressive neurodegenerative disorder. It is caused primarily by the degeneration of dopaminergic neurons in the substantia nigra. This leads to dopamine deficiency in the striatum, disrupting basal ganglia circuits responsible for smooth and coordinated movement. The classical motor symptoms include resting tremor, bradykinesia, rigidity, and postural instability (Hariz & Blomstedt, 2022). Global prevalence is rising, partly due to population aging. Estimates exceed 5–10 million individuals worldwide (Foote et al., 2025). Symptoms typically begin mildly but progress over time, leading to increasing dependence and disability. Although no cure exists, current treatments including medication, rehabilitation, and neuromodulation can substantially improve symptom control in those affected by Parkinsons Disease. These treatments help maintain functional independence and enhance quality of life for individuals living with PD. Why DBS for Parkinsons Disease? Deep brain stimulation (DBS) is a key treatment option for people with Parkinson’s disease (PD). It is for those whose symptoms are no longer adequately controlled with medication alone. As PD progresses, many patients develop motor fluctuations. DBS is especially valuable because it is adjustable, reversible, and long-term. Unlike lesion-based procedures, DBS does not permanently destroy brain tissue; instead, clinicians can fine-tune stimulation parameters to match the patient’s symptom severity and progression over time. Both the subthalamic nucleus (STN) and the globus pallidus internus (GPi) are well-established DBS targets, and stimulation of either region can significantly improve bradykinesia, rigidity, tremor, and motor complications (Deuschl et al., 2006; Weaver et al., 2012). Patients who previously experienced unpredictable medication response often report smoother control and more stable daily functioning after DBS. Another major advantage of DBS is its impact on medication burden. Many individuals undergoing STN DBS are able to reduce their dopaminergic medication by 30–50%, which helps decrease dyskinesias and medication-related side effects (Perestelo-Pérez et al., 2014). GPi DBS, while usually associated with less medication reduction, can provide strong suppression of dyskinesias even without lowering drug dosage (Wagle Shukla et al., 2025). Beyond motor symptoms, DBS can improve sleep quality and reduce pain. It enhances daily independence, leading to better overall quality of life. DBS Procedure & Targets Deep brain stimulation (DBS) works by delivering controlled electrical pulses to specific brain regions involved in Parkinson’s disease motor circuitry. The procedure is typically performed by a multidisciplinary team. This includes a movement-disorder neurologist, a functional neurosurgeon, and DBS programming specialists. The two primary targets for Parkinson’s disease are the subthalamic nucleus (STN) and the globus pallidus internus (GPi). STN DBS is widely used because it can improve motor symptoms and often allows a reduction in dopaminergic medication. GPi DBS is equally effective for improving motor function but is especially beneficial for controlling dyskinesias and may have fewer mood or cognitive side effects in certain patients (Perestelo-Pérez et al., 2014). A third target, the ventral intermediate nucleus (VIM) of the thalamus, is generally reserved for tremor-dominant disease, particularly in patients whose primary disabling symptom is medication-resistant tremor (Deuschl et al., 2006). The surgical process involves implanting thin electrodes through a small skull opening using stereotactic navigation. High-resolution MRI and CT imaging guide the trajectory, and some centers use microelectrode recordings to refine accuracy. After placement, the electrodes are connected to an implantable pulse generator (IPG) positioned under the skin of the chest (Weaver et al., 2012). Programming begins a few weeks after surgery. Clinicians adjust frequency, pulse width, and amplitude to optimize benefit while minimizing side effects. Modern systems incorporate directional leads, which allow current steering toward therapeutic pathways and away from regions causing speech or balance problems. These advances have expanded the therapeutic window and improved long-term tolerability (Foote et al., 2025). Overall, precise targeting, patient selection, and expert programming are key to achieving durable and meaningful clinical outcomes with DBS. Clinical Outcomes & Long-Term Efficacy Deep brain stimulation (DBS) provides some of the most consistent and durable clinical benefits available for patients with Parkinson’s disease. Across multiple randomized controlled trials and long-term cohort studies, stimulation of either the subthalamic nucleus (STN) or globus pallidus internus (GPi) leads to marked improvement in cardinal motor symptoms. This includes tremor, rigidity, and bradykinesia. One of the most clinically meaningful advantages of DBS is its effect on motor fluctuations. Patients commonly experience smoother transitions throughout the day, fewer sudden “off” episodes, and significant relief from levodopa-induced dyskinesias. GPi DBS is particularly effective for dyskinesia suppression, while STN DBS often allows a 30–50% reduction in medication dosage, contributing to reduced side effects and improved overall tolerability (Perestelo-Pérez et al., 2014). Long-term studies consistently show that DBS maintains its therapeutic impact for many years. A recent five-year evaluation demonstrated sustained improvement in motor symptoms and functional performance. Importantly, DBS has been shown to positively influence quality of life. Improvements in mobility, independence, speech-related function, and participation in daily activities are consistently reported across both STN and GPi cohorts. Patients benefit not only from reduced symptom burden but also from greater reliability in day-to-day function, fewer medication side effects, and improved sleep, mood, and energy levels documented in modern neuromodulation research (Foote et al., 2025). Overall, the evidence demonstrates that DBS is a highly effective and durable therapy for appropriately selected patients. It provides substantial short-term improvements in motor control and long-term stability of benefit, outperforming medication adjustments alone and offering sustained gains in mobility, independence, and quality of life. Side Effects & Safety Profile Deep brain stimulation (DBS) is considered a safe and well-established therapy for Parkinson’s disease when performed in experienced centers. Surgical risks include infection, lead misplacement, wound complications, and rarely intracranial hemorrhage. Large prospective trials such as those by Deuschl et al. and Weaver et al. confirmed that serious surgical complications remain uncommon and comparable to other stereotactic neurosurgical interventions (Deuschl et al., 2006; Weaver et al., 2012). Most side effects are stimulation-related rather than surgical. Because DBS delivers current to deep brain structures, unintended spread of stimulation can cause speech difficulty, balance problems, muscle tightness, tingling sensations, or transient mood changes. These effects are typically

Essential Tremor

Essential Tremor Essential tremor (ET) is one of the most common movement disorders, with a global prevalence of roughly 0.9%. It is increasingly frequent in older age groups (Ferreira et al., 2019; Wong et al., 2020). It is defined as an isolated, bilateral upper extremity action tremor of at least three years’ duration. This can occur with or without tremor in other body regions and without additional neurological signs such as parkinsonism, dystonia, or cerebellar ataxia (Wong et al., 2020). Tremor typically involves the hands but may extend to the head, voice, jaw, and lower limbs. This leads to difficulties in writing, drinking, eating, fine motor tasks, and sometimes gait. Although ET is not life-threatening, it is often progressive. Longitudinal data suggest a 2–5% per-year increase in arm tremor amplitude over time (Wong et al., 2020). Many patients adapt, but a substantial subset develop socially embarrassing and functionally disabling tremor. This interferes with employment and independence (Dallapiazza et al., 2019). First-line pharmacologic therapy consists mainly of propranolol and primidone. These treatments yield mean tremor amplitude reductions of about 55–60%, and up to approximately 70% when combined (Wong et al., 2020; Martinez-Nunez et al., 2024). Nevertheless, only about half of patients achieve satisfactory functional benefit. A large proportion discontinue medication due to limited efficacy or side effects. This treatment gap underlies the need for neuromodulation strategies such as deep brain stimulation (DBS) in carefully selected, medication-refractory ET. Why Deep Brain Stimulation for Essential Tremor? Understanding Essential Tremor: Symptoms and Diagnosis Deep brain stimulation is an established surgical option for patients with medication-refractory, functionally disabling ET. This typically occurs after failure or intolerance of adequate trials of propranolol, primidone, and other guideline-supported agents (Ferreira et al., 2019; Wong et al., 2020). Up to 50–55% of patients remain significantly symptomatic despite optimized pharmacotherapy. This makes them potential DBS candidates (Martinez-Nunez et al., 2024). Evidence syntheses consistently position DBS among the most effective interventions for severe ET. In the large Movement Disorder Society evidence-based review, unilateral thalamic (VIM) DBS was classified as “possibly useful” for limb tremor, alongside radiofrequency and MRI-guided focused ultrasound thalamotomy (Ferreira et al., 2019). Recent evidence is highly supportive of DBS. A 2024 Bayesian network meta-analysis comparing 33 randomized trials found that DBS provided the largest overall reduction in tremor severity among all studied treatments. It ranked first in relative efficacy, outperforming both medications and other interventional procedures (Zhang et al., 2024). Clinically, VIM DBS offers strong and predictable outcomes. Most patients experience a 53–63% reduction in tremor within the first year after unilateral implantation. In contrast, bilateral DBS—treating both upper limbs—typically achieves 66–78% improvement. Long-term follow-up studies further show that these benefits are generally maintained for more than five years. The majority of patients continue to experience meaningful tremor control. A small subset may show mild habituation over time, but overall tremor suppression and patient satisfaction remain high (Wong et al., 2020; Børretzen et al., 2014). Importantly, DBS is adjustable and reversible. This allows postoperative programming to optimize tremor control while minimizing stimulation-induced dysarthria, ataxia, and gait disturbance (Chandra et al., 2022; Martinez-Nunez et al., 2024). For a neuromodulation-focused practice, DBS therefore occupies a central role as the preferred bilateral, non-ablative intervention in ET patients whose tremor remains disabling despite best medical therapy, particularly when long-term quality of life and flexibility of treatment are prioritized over single-session lesioning approaches. DBS Procedure & Targets in Essential Tremor Deep brain stimulation (DBS) for essential tremor is usually done by a team that includes a movement-disorder neurologist, a functional neurosurgeon, and DBS programmers. Before surgery, doctors confirm that the tremor is truly essential tremor and not another condition such as Parkinson’s disease or dystonia. They also check that medications have already been tried without enough benefit, perform a brain MRI, and evaluate memory and mood to make sure DBS is safe (Wong et al., 2020; Chandra et al., 2022). The most common DBS target is the ventral intermediate nucleus (VIM) of the thalamus. This area is part of the brain’s tremor circuit and receives signals from the cerebellum through the dentato-rubro-thalamic tract (DRTT). Because of its location, stimulating the VIM can effectively interrupt the abnormal tremor signals (Iorio-Morin et al., 2020). Some centers also use the posterior subthalamic area (PSA) or the caudal zona incerta (cZi). These targets may sometimes provide strong tremor reduction with lower stimulation settings, but they can also cause more balance or speech problems if the stimulation spreads too far (Wong et al., 2020; Martinez-Nunez et al., 2024). During surgery, the electrode is placed using MRI/CT images and sometimes microelectrode testing to confirm the correct spot. The lead is then connected to a small battery (IPG) placed under the skin of the chest (Chandra et al., 2022). Modern DBS systems often use directional leads, which allow doctors to steer the current more precisely. This helps improve tremor control while reducing side effects like tingling or slurred speech (Wong et al., 2020; Iorio-Morin et al., 2020). Programming starts a few weeks after surgery and continues over several follow-up visits. Doctors adjust the frequency (usually around 130 Hz), pulse width, and amplitude to find the best balance between tremor control and comfort. Directional stimulation and newer programming algorithms have made this process even safer and more effective (Chandra et al., 2022; Martinez-Nunez et al., 2024). Clinical Outcomes & Long-Term Efficacy of DBS in Essential Tremor Deep brain stimulation (DBS) provides one of the most potent and durable therapeutic effects for medication-refractory essential tremor (ET), consistently outperforming pharmacologic therapy and most ablative procedures. Across decades of observational series, controlled studies and meta-analyses, VIM–PSA–cZi neuromodulation has demonstrated robust tremor reduction, meaningful functional improvement and sustained quality-of-life gains in appropriately selected patients. Short- and Mid-Term Outcomes Deep brain stimulation provides strong tremor control early after surgery. Most studies show that unilateral VIM DBS reduces tremor by about 53–63% within the first year, while bilateral DBS improves tremor by about 66–78%, since both upper limbs are treated (Dallapiazza et al., 2019). These improvements

What Is DBS? Deep Brain Stimulation

What Is DBS? What Is DBS? Understanding the basics of What Is DBS in neuromodulation therapy. Deep brain stimulation (DBS) is a neurosurgical neuromodulation therapy that delivers controlled electrical pulses to targeted subcortical nuclei through chronically implanted electrodes. Originally adapted from cardiac pacemaker technology, DBS enables direct, adjustable modulation of dysfunctional neural circuits without creating permanent lesions. Modern systems consist of intracranial leads, extension cables, and an implantable pulse generator capable of delivering continuous or intermittent stimulation with high temporal precision (Krauss et al., 2021). What Is DBS? This question is essential for anyone looking to understand deep brain stimulation. Clinically, DBS has transformed the management of several neurologic and neuropsychiatric conditions. It is an established, guideline-supported treatment for Parkinson’s disease, essential tremor, dystonia, and medically refractory epilepsy, and it carries Humanitarian Device Exemptions for obsessive-compulsive disorder (Miocinovic et al., 2013; Sandoval-Pistorius et al., 2023). Worldwide, more than 160,000 individuals have undergone DBS implantation, reflecting its growing acceptance as both a therapeutic and investigative tool (Lozano et al., 2019). In summary, What Is DBS? It is a transformative approach for managing various neurologic conditions. The defining strength of DBS lies in its capacity to interface with pathological brain circuits in real time. Unlike ablative surgery, DBS allows reversible, titratable adjustments of stimulation amplitude, frequency, and pulse width to optimize symptom control while minimizing side effects. Advances such as directional leads, rechargeable generators, and sensing-enabled closed-loop systems have expanded DBS’s precision and potential applications (Krauss et al., 2021; Sandoval-Pistorius et al., 2023). When discussing treatments, one might ask, what is DBS? It offers numerous advantages over traditional methods. Through its dual role as both a therapeutic modality and a window into human circuit physiology, DBS has emerged as one of the most significant innovations The topic of What Is DBS continues to gain attention in both clinical and research settings. History of DBS Throughout its history, What Is DBS has evolved significantly, marking milestones in neurosurgery. The history of deep brain stimulation (DBS) reflects a gradual convergence of neurosurgical innovation and circuit-based neuroscience. Early attempts to modulate deep brain structures date back to the mid-20th century, when pioneers such as Pool and Delgado explored chronic stimulation of subcortical nuclei for psychiatric disorders, pain, and behavioral modulation. These initial experiments were constrained by unreliable hardware and limited understanding of functional neuroanatomy, yet they established the conceptual foundation that abnormal neural circuits could be therapeutically influenced (Krauss et al., 2021). As we consider early techniques, let’s reflect on what is DBS and its foundational principles. By the 1950s and 1960s, chronic stimulation was used as a diagnostic tool to localize optimal targets for subsequent lesioning procedures. Investigators such as Sem-Jacobsen and Bechtereva demonstrated that high-frequency stimulation could temporarily suppress tremor or rigidity, foreshadowing the principle that electrical modulation itself—not only ablation—could alleviate symptoms (Lozano et al., 2019). The modern era began in 1987, when the Grenoble group led by Benabid showed that thalamic stimulation could produce durable tremor control comparable to thalamotomy but without permanent tissue destruction (Miocinovic et al., 2013). Throughout the 1990s, advances in stereotactic imaging, microelectrode recording, and implantable pulse generator technology enabled reliable stimulation of deeper and more complex targets, such as the subthalamic nucleus and globus pallidus internus. These developments culminated in regulatory approvals for DBS in essential tremor, Parkinson’s disease, dystonia, and later obsessive-compulsive disorder. Entering the 21st century, the field shifted toward technological refinement—directional leads, rechargeable generators, and sensing-enabled systems—transforming DBS from a symptomatic therapy into a platform for interrogating and modulating dysfunctional brain networks (Sandoval-Pistorius et al., 2023). This historical trajectory continues to shape the evolution of DBS as both a clinical and scientific tool. To clarify, what is DBS? It is both a clinical application and a research focus. Mechanisms of Action and Rationale for Neuromodulation Understanding what is DBS helps in appreciating its therapeutic potential and mechanisms. Deep brain stimulation (DBS) improves symptoms by modulating dysfunctional brain circuits rather than destroying tissue, making it a uniquely flexible neurosurgical therapy. Although the exact mechanism differs by condition, decades of research indicate that DBS acts through a combination of electrical, cellular, and large-scale network effects. At the fundamental level, high-frequency stimulation generates controlled action potentials that override abnormal firing patterns within pathological circuits. This “network stabilization” effect dampens the excessive low-frequency oscillations that are characteristic of disorders such as Parkinson’s disease, dystonia, and essential tremor (Lozano et al., 2019). DBS leads are typically placed in nodes that sit at the center of critical motor or limbic pathways—most notably the subthalamic nucleus (STN), globus pallidus internus (GPi), ventral intermediate nucleus (VIM) of the thalamus, and anterior nucleus of the thalamus (ANT). These structures serve as communication hubs within basal ganglia–thalamo–cortical loops, making them ideal targets for circuit-level neuromodulation. Electrical stimulation also alters synaptic behavior. High-frequency pulses reduce the effective transmission of aberrant rhythmic signals through synaptic filtering and neurotransmitter depletion, while still allowing physiologic information to pass through the circuit (Krauss et al., 2021). Beyond neurons, DBS influences astrocytes, microvasculature, and neurochemical signaling, contributing to the delayed improvements seen in dystonia, psychiatric disorders, and epilepsy—conditions where symptom relief often unfolds gradually over weeks or months (Sandoval-Pistorius et al., 2023). Modern imaging and computational modeling demonstrate that DBS works not by targeting a single nucleus, but by modulating distributed structural and functional networks. Effective outcomes depend on engaging specific fiber pathways—supporting the idea that DBS is fundamentally a “circuit therapy” (Sandoval-Pistorius et al., 2023). This network-level perspective explains why stimulation of a highly focal brain region can influence motor, cognitive, and affective systems simultaneously. The rationale for neuromodulation stems from this understanding of brain disorders as circuitopathies, where abnormal oscillations and connectivity patterns drive clinical symptoms. DBS offers a reversible, adjustable method to normalize these circuits without the risks of permanent lesions. Its programmability—fine-tuning amplitude, pulse width, frequency, and directionality—allows clinicians to optimize therapy over time, balancing efficacy and side effect control (Miocinovic et al., 2013). Overall, DBS works through a multimodal interplay of electrical, synaptic,